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Abstract: This manuscript reports an effective new al-
ternative for the management of bone infection by the
development of an antibiotic nanocarrier able to pene-5
trate bacterial biofilm, thus enhancing antimicrobial effec-
tiveness. This nanosystem, also denoted as “nanoantibi-
otic”, consists in mesoporous silica nanoparticles (MSNs)
loaded with an antimicrobial agent (levofloxacin, LEVO)
and externally functionalized with N-(2-aminoethyl)-3-10
aminopropyltrimethoxysilane (DAMO) as targeting agent.
This amine functionalization provides MSNs of positive
charges, which improves the affinity towards the nega-
tively charged bacteria wall and biofilm. Physical and
chemical properties of the nanoantibiotic were studied15
using different characterization techniques, including X-
ray diffraction (XRD), transmission electron microscopy
(TEM), N2 adsorption porosimetry, elemental chemical
analysis, dynamic light scattering (DLS), zeta (ζ )-potential
and solid-state nuclear magnetic resonance (NMR). “In20
vial” LEVO release profiles and the in vitro antimicrobial
effectiveness of the different released doses were investi-
gated. The efficacyof thenanoantibiotic against a S. aureus
biofilmwas also determined, showing the practically total
destruction of the biofilm due to the high penetration abil-25
ity of the developed nanosystem. These findings open up
promising expectations in the field of bone infection treat-
ment.
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1 Introduction
Bone infection is a potentially dangerous affection that
keeps defying the scientific community due to its status
as a clinical pathology with important involvements in the 35
socioeconomic field [1–3]. The main trigger agent of this
issue is the Staphylococcus aureus (S. aureus) pathogen [4,
5], and according to databases of PubMed and Scopus, the
annual incidence of invasive infections of S. aureus varies
from 1.6 to 29.7 cases of each 100,000, depending on the 40
studied location. Actually, they come to be the 2.8 from
43% of total infection in bone and joint [6].
Bone infection remains a substantial challenge be-
cause of the shortcomings found in current therapies,
which relies on the systemic administration of antibiotics 45
and surgery. They are commonly associated to high rate of
side effects in the patients, long hospital stays and high
morbidity [7].
The development of new strategies that permit to opti-
mize the antimicrobials concentration in the infection site 50
without increasing toxicity would represent a significant
advance in the management us such infections. In this
context, the entering of nanomedicine into this scenario
has revolutionized the scientific researchand it is expected
that in the forthcoming decades transforms the pharma- 55
ceutical and biotechnological industries. The reason un-
derlying this revolution relies on the possibility of circum-
venting the main limitations of conventional medicine,
such as the lack of specificity, narrow therapeutic window,
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Figure 1: Representative depiction of the mechanism of action of the nanoantibiotic against bacterial biofilm.
low solubility and stability, unappropriated pharmacoki-
netics and diverse side effects of drugs [8]. Albeit during
the last 40 years promising results have been achieved,
the clinical application of nanotechnology, in its broad-
est sense, remains an enormous defy. This fact can be ex-5
plained because nanomedicine requires complex and spe-
cific technological solutions that make difficult its phar-
maceutical development [9]. The application of nanoma-
terials in medicine has provided more than 250 products
already approved or in different phases of clinical trials.10
Nowadays, one of the most important challenges in
bone infection therapy is the design of nanocarriers able
to protect, transport and release antimicrobial agents in a
controlled way once they reached the target (bacteria and
biofilm) [8, 10]. Among nanocarriers, mesoporous silica15
nanoparticles (MSNs) are excellent candidates to develop
targeted stimuli-responsive drug delivery systems [9, 11–
19]. They exhibit unique properties such as high specific
surface area, large pore volume, tunable pore structures
andeasilymodifiable surfacedue to thepresence of silanol20
groups (Si-OH) [10, 20].Moreover,MSNshavebeendemon-
strated to be biocompatible both in vitro and in vivo [21–23]
and exhibit adequate stability in different biological me-
dia [24, 25].
Herein, we designed a nanosystem named “nanoan- 25
tibiotic” as a new therapeutic alternative to fight against
bone infection. This nanoantibiotic, which is based on
MSNs, combines an antimicrobial agent with an amine
functionalization as targeting agent to recognize the bac-
teria. Levofloxacin (LEVO) antibiotic, a wide range fluo- 30
roquinolone usually employed in osteomyelitis and im-
plant associated bone infections due to its strong cortical
bone affinity [26] was used. The used targeting agent, N-(2-
aminoethyl)-3-aminopropyltrimethoxysilane (DAMO), de-
ploys positively charged amine groups on the MSN sur- 35
face that enables attractive electrostatic interactions with
the bacteria wall and/or biofilm, exhibiting negative den-
sity charge. The hypothesis of the current research work is
schematically depicted in Figure 1.
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Figure 2: Scheme of the DAMO grafting to the Si-OH present on the MSN external surface.
2 Materials and Methods
2.1 Synthesis and functionalization of MSNs
Pristine MSNs, denoted as MSN, were synthesized via
the modified Stöber method [27]. Briefly, 1 g of cetyl
trimethylammonium bromide (CTAB, Sigma-Aldrich) was5
dissolved in 480 mL Milli-Q water (resistivity 18.2 MΩ cm)
containing 3.5 mL of a 2M solution of NaOH (99%, Sigma-
Aldrich). The mixture was kept under magnetic stirring
(400-600 rpm) at 80∘C for 45 min. Afterwards, 5 mL of
tetraethyl orthosilicate (TEOS, 98%, Sigma-Aldrich) were10
addedwith a pump injector NE-300 (Just Infusion) at a rate
of 0.33 mL/min, maintaining the same conditions of tem-
perature and stirring for 2 h. Later, the flask was cooled
down rapidly and its content was centrifuged in a cen-
trifuge Heraeus Multifugue X3 (Thermo Fisher Scientific)15
at 10,000 rpm and 10∘C for 10 min in 3 cycles. Between
each cycle, the content was resuspended with 80 mL of
absolute ethanol (99.5%, PanReac), for its washing. Fi-
nally, the obtained product was dried in a vacuum stove
(Vaciotemp-T JP Selecta, ICT) at 30∘C. To provide theMSNs20
fluorescent properties for detecting them using confocal
microscopy, this synthesis route was modified by adding
fluorescein. For this purpose, 1 mg of fluorescein isoth-
iocyanate (FITC, Sigma-Aldrich) was added to 2.2 µL of
(3-aminopropyl)triethoxysilane (APTES, 99%, ABCR) and25
100 µL of absolute ethanol under constant stirring at 200
rpm for 2h at room temperature (RT) and protected from
light. After this time, 5 mL of TEOS were added until com-
plete homogenization was obtained. This solution was in-
jected in the synthesis flask containing the aqueous solu-30
tion of the structure-directing agent in basic medium, as
indicated for the preparation of the MSN.
To provide MSN of targeting properties towards
bacteria, their surface was functionalized with N-(2-
aminoethyl)-3-aminopropyltriethoxysilane (DAMO, 95%,35
ABCR) by means of a post-synthesis grafting under an-
hydrous conditions and inert atmosphere [28]. The reac-
tion was produced through the condensation between the
DAMO molecules and the silanol groups on the MSN sur-
face, as indicated in Figure 2. The functionalization was 40
carried out before the surfactant removal from the meso-
porous cavities, in such a way that the material is only
functionalized in the exterior, leaving the pores free after
the extraction process [29]. The amount of DAMO used for
the functionalization process was calculated taking into 45
account the average superficial density of silanol groups in
theMSNs (4.9 SiOH/nm2) [30] and the fact that eachDAMO
molecule mainly condenses with three Si-OH groups (in
good agreement with the results derived from 29Si NMR,
vide infra). Briefly, 1 g ofMSNwas dried in a three-mouthed 50
flask with round bottom at 80∘C and vacuum conditions
for 24 h. Then, three cycles alternating vacuum and N2
were performed. 200 mL of anhydrous toluene (99.8%,
Sigma-Aldrich) were added and the flask was immersed
in a ultrasound bath for 1 h. Afterwards, 0.8 mL of DAMO 55
were added and the flask was left at 110∘C with reflux for
24 h. Finally, the product was centrifuged by successive
washing cycles with isopropanol, ethanol and methanol,
respectively. The product was left to dry for 24 h under vac-
uum at 30∘C. The surfactant extraction was performed via 60
cationic exchange. For this purpose, an extracting solution
containing 100mL of deionized water, 1.9 L of ethanol and
20 g of NH4NO3 (99.5%, Sigma-Aldrich) was made. Then,
1 g of MSNs was added to 600 mL of extracting solution.
The suspension was kept during 24 h with a reflux (80∘C) 65
and magnetic stirring. Finally, the product was washed 3
times with ethanol and was left to dry for 24 h at 30∘C in a
vacuum oven.
2.2 Materials Characterization
The structural characterizationwas performed using X-ray 70
diffraction (XRD) in a diffractometer Philips X’pert Plus
working with Kα radiation of Cu (λ = 1.54 Å) at 40 kV
and 20 mA, in the range 0.6-7∘ with a contact time of 5 s
and transmission electronic microscopy (TEM) in a JEOL
JEM 1400 microscope with a voltage accelerator of 120 kV 75
with a CCD of 2048 x 2048 pixels. The textural proper-
ties were determined using porosimetry of N2 adsorption
at −196∘C using a Micromeritics ASAP 2020 analyzer (Mi-
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Figure 3: Sequential process of functionalization, extraction and LEVO loading of MSNs affording MSN-DAMO@LEVO.
cromeritics Co.). The surface areawas calculated using the
Brunauer-Emmet-Tellet (BET) method [31]. The total pore
volume (VT) was estimated from the N2 adsorbed at a rel-
ative pressure of 0.97. The pore diameter (Dp) was deter-
mined using the Barret-Joyner-Halenda (BJH)method. The5
hydrodynamic sizewas determined via dynamic light scat-
tering (DLS) in a Zetasizer Nano ZS (Malvern Instruments
Ltd.) equipped with a 633 nm laser. The same equipment
was used tomeasure the ζ -potential. The chemical compo-
sition was determined via elemental chemical analysis in10
a Perkin-Elmer 2400 CHNS thermoanalyzer. The changes
in the chemical environments of the Si and C atoms of
the different samples were studied through 29Si (single
pulse, SP, and cross-polarization, CP) and 1H→ 13C solid-
state nuclear magnetic resonance (NMR) in a Bruker AV-15
400-WB spectrometer, using spinning speeds of 10 and 12
kHz and observation frequencies of 79.49 and 100.62 MHz,
respectively. The 29Si spectra were obtained using a sin-
gle pulse sequence (29Si SP magic angle spinning, MAS,
NMR), whilst the 13C ones were obtained using a 1H→13C20
CP MAS NMR sequence. The time periods between succes-
sive collections were 5 and 3 ms for 29Si and 13C, respec-
tively, and the total number of scans was approximately
1,000 for both cases.
2.3 Levofloxacin loading and drug release25
The loading of LEVO (≥ 98.0%, Sigma-Aldrich) inside the
matrix of MSN and MSN-DAMO was done via the impreg-
nation method [32]. 125 mg of MSN and MSN-DAMO was
suspended in 25 mL of a drug solution (26.1 mg/mL) in the
absence of light under magnetic stirring during 24 h at RT,30
and the resulting samples were denoted as MSN@LEVO
and MSN-DAMO@LEVO, respectively. Figure 3 schemat-
ically shows the full process followed to obtain MSN-
DAMO@LEVO.
The release of LEVO from each of the matrices was 35
done under in vitro conditions at 37∘C and physiological
pH (pH 7.4). A solution of 4mg of the loadedmaterials was
prepared in 500 µL of phosphate buffered saline (PBS 1x,
Sigma Aldrich). 170 µL of this suspension was introduced
in a release cap and placed in a bucket containing 3.6 mL 40
of PBS separated by a dialysis membrane that only allows
for the diffusion of LEVO molecules. The system was kept
at 37∘C under magnetic stirring and the concentration of
released drug was monitored via fluorescence in a Biotek-
Powerwave XSwith the programme Gen5 (v.1.00.14), using 45
a λ(exc)=292 nm y λ(em)=494 nm. To determine the LEVO
concentration a calibration curve in the 12 to 0.02 µg/mL
range was performed. The “in vial” release study was car-
ried out by renewing the media at given times. With the
aim of determining the effectiveness of the different re- 50
leased LEVOdoses against bacteria growth, 100 µL of each
dose was inoculated in 900 µL of suspension contain-
ing 108 bacteria/mL in PBS, which was later incubated
overnight at 37∘C and under orbital stirring at 200 rpm.
This study was performed with Gram-positive (S. aureus) 55
and Gram-negative (E. coli) bacteria. The presence (or ab-
sence) of bacteria, along with its quantification was done
by means of counting the colony forming units (CFUs) on
tryptic soy agar (TSA, Sigma-Aldrich) plates. For this pur-
pose 10 µL of this solution was seeded in TSA plates, be- 60
ing incubated at 37∘C overnight, with a later counting of
the CFUs. All the assays were done in triplicate with their
respective control samples.
2.4 In vitro antimicrobial tests
The nanoantibiotic effectiveness was determined using 65
three different approaches: targeting to the bacteria wall,
targeting to bacterial biofilm, and antimicrobial activity
against preformed S. aureus biofilm.
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Targeting to bacteria: In this study Gram-negative bac-
teria E. coli ATCC25922 collection strain was used. Before
the assays, disk-shaped cover glasses (9 mm diameter)
were sterilized by UV-light and then incubated with poly-
D-lysine (0.3 mL per well from a 0.1 mg/mL stock solution5
in Dulbecco’s Phosphate Buffered Saline, Sigma-Aldrich)
for 90 min at 37 ∘C. Then, the excess poly-D-lysine was re-
moved by washing with sterilized Milli-Q water and the
cover glasses were left to dry overnight in a sterile envi-
ronment. Poly-D-Lysine treated cover glasses were placed10
in 24 well culture plates (CULTEK). Then, 500 µL of the 108
bacteria/mL solutionwas added onto each cover glass and
subsequently 500 µL of FMSNs and FMSNs-DAMO suspen-
sions in PBS at different concentrations (5 and 10 µg/mL)
were also inoculated and incubated at 37∘C and 200 rpm15
under orbital stirring during 90min. Then, each glass-disk
was washed twice with sterile Hank’s balanced salt solu-
tion (HBSS, Sigma-Aldrich) and 1mL of HBSS was added.
FM 4-64FX dye (0.2 mL from a 5 µg/mL stock solution in
HBSS, Invitrogen) was added to stain the bacteria wall in20
red and incubated on ice for 10 min under orbital stirring.
Later on, the cover glasses were washed with HBSS and
fixed in 2% wt/vol paraformaldehyde in PBS for 10 min at
RT. The fixative was removed with HBSS twice and 0.5 mL
HBSS was added to each well before imaging. The sam-25
ples were examined in an Olympus FV1200 confocal mi-
croscope.
Targeting to bacterial biofilm: S. aureus ATCC28213
strain was used for these studies. After treating with poly-
D-lysine, as abovedescribed, the cover glasseswereplaced30
in a 24 well culture plate and 500 µL of a solution of bac-
teria with 108 bacteria per mL were added to each plate
during 48 h. Then, 500 µL of fluorescent MSN and MSN-
DAMO suspensions at different concentrations (10 and
20 µg/mL) in PBS was added and incubated at 37∘C under35
orbital stirring at 200 rpm. Themediumusedwas 66%TSB
+ 0.2% glucose (wt/vol) to promote robust biofilm forma-
tion. After 90 min, the treated cover glasses were washed
three times with sterile PBS, stained with 5 µL/mL cal-
cofluor (calcofluor white, Sigma-Aldrich) and incubated40
during 15 min. The calcofluor stained the mucopolysac-
charides of the biofilm (extracellular matrix in blue). The
samples were examined in an Olympus FV1200 confocal
microscope. Control biofilms without nanoparticles was
also observed.45
Antimicrobial effects against Gram positive S. aureus
biofilm: Effectiveness of the complete nanosystems con-
taining both targeting and antimicrobial LEVO agents
against bacterial biofilm was determined. For these pur-
pose, S. aureus biofilms were developed, as above de- 50
scribed. Then, 0.5 mL of the suspension of nanoparti-
cles in PBS at a concentration 10 µg/mL was added. Af-
ter 90 min of incubation, the cover glasses were washed
three times with sterile PBS, stained with a 3 µL/mL of
Live/Deadr Bacterial Viability Kit (BacklightTM, Invitro- 55
gen) and 5 µL/mL of calcofluor solution was added. Both
reactants were incubated during 15 min at RT. Biofilm
formation was examined in an Olympus FV1200 confo-
cal microscope. Bacterial biofilm control was also stud-
ied. Eight photographs (60x magnification) of each sam- 60
ple were taken. The surface area covered by adhered bac-
teria was calculated using ImageJ software (National Insti-
tute of Health, Bethesda, MD). The experiments were per-
formed in triplicate.
3 Results and discussion 65
3.1 Sample Characterization
The structural and textural characterization of MSNs be-
fore and after DAMO functionalization was performed us-
ing TEM, XRD and N2 adsorption porosimetry (Figure 4).
TEM images showa sphericalmorphology of nanopar- 70
ticles sized ca. 120 nm, showing a honeycomb disposition
of the inner channels that follow a hexagonal symmetry.
XRD diagrams confirm that structure, showing diffraction
maxima at 2.3∘, 3.9∘ and 4.5∘ which can be indexed as
the 10, 11 and 20 reflections, respectively, of a 2D hexag- 75
onal structure p6mm plain group. In terms of textural
properties, the adsorption-desorption N2 isotherms pro-
files are associated to mesoporous MCM-41 type materials
with cylindrical parallel pores. Table 1 contains structural
parameters (surface area(SBET), pore volume (VP), pore di- 80
ameter (DP)) of samples before andafter functionalization,
showingadecrease of themafterDAMOgrafting.Addition-
ally, using the lattice parameter (a0) obtained by XRD and
Dp, we can obtainwall thickness,which increases after the
functionalization process. We can observe a reduction on 85
hydrodynamic size (DH) of MSN-DAMO against MSN due
to DAMO’s hydrophilic behavior, which provides a higher
colloidal stability. The ζ -potential changemeans a change
on the sign of the surface charge density, which confers
MSN-DAMO of potential bacterial targeting capability. 90
Quantitative determination of functional groups, per-
formed by elemental chemical analysis, indicated that the
amount of DAMO incorporated into MSN-DAMO was 286
mg/g. With the aim of evaluating the modification in the
chemical environments of MSNs we carried out solid state 95
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Figure 4: (A) TEM images, (B) XRD patterns and (C) N2 adsorption isotherms of MSN and MSN-DAMO.
Table 1: Lattice parameter (a0), hydrodynamic size (DH ), textural properties, ζ -potential and weight (%) of DAMO and LEVO for the different
samples.














MSN 4.55 190 937 0.85 2.4 2.1 −36.4 0 0
MSN-DAMO 4.68 141 670 0.40 2.1 2.5 37.4 28.6 0
MSN@LEVO 4.50 183 798 0.73 2.6 1.9 −37.0 0 3.18
MSN-DAMO@LEVO 4.51 139 294 0.25 1.9 2.6 +35.1 28.6 5.03
NMR studies. Figure 5 shows CP-MAS and SP-MAS of 29Si
spectra of samples and Table 2 displays the relative abun-
dance of Si species in the different environments derived
from the deconvolution and subsequent integration of the
resulting peaks. Both MSNs spectra show resonances at5
−94, −102 y −111 ppm, which are assigned to silicon atoms
in Q2, Q3 and Q4 environments. Q2 and Q3 structural units
are ascribed to the Si-OH groups present on the MSN sur-
face. The relative abundances of Si atoms in Q2 and Q3
environments decrease in the case of functionalized sam- 10
ple, due to the condensation reaction of DAMO moieties
with the Si-OH groups of MSN surface. Furthermore, MSN-
DAMO spectrum shows two additional peaks associated to
organosiloxane groups T2 and T3 at ca. −59 and −68 ppm,
respectively. These data confirm the presence of covalent 15
unions between the MSN surface and DAMOmolecules.
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Figure 5: Left) 1H→29Si-CP-MAS NMR results of MSN and MSN-DAMO that indicate the maxima position of Qn y Tm. Right) 1H→29Si-SP-MAS
NMR results of MSN and MSN-DAMO.
Table 2: Relative abundance of species of Si on Qn and Tm environ-
ments obtained from the deconvolution of the 29Si SP-MAS NMR
signals.
Sample % T2 % T3 %Q2 %Q3 %Q4
MSN 0 0 13 31 56
MSN-DAMO 5 12 6 19 58
In MSN spectrum maxima corresponding to remain-
ing CTAB are observed, while in MSN-DAMO signals asso-
ciated to various C atoms of DAMO appear, whose assigna-
tion is also included in Figure 6.
3.2 Levofloxacin loading and release assays5
The amount of LEVO incorporated to samples was de-
termined by elemental chemical analysis, resulting in
31.8 mg/g and 50.3 mg/g for MSN@LEVO and MSN-
DAMO@LEVO, respectively. Figure 7 represents the release
curves of LEVO from the different matrices. The results
show that LEVO release from MSN is slower than from
MSN-DAMO, which also produces a partial retention of the
drug in the former. On the contrary, drug release profile
from MSN-DAMO follows a typical diffusion model, where
almost the total loaded LEVO is released after 72 h of as-
say. Both release curveswere analyzed and comparedwith








where w(t) is the amount of LEVO released at t time, w0 is
the initial amount of loaded drug,A is themaximumLEVO
release, k is the release kinetic constant and δ is a dimen-
sionless parameter of non-ideality that characterizes the
release. 10
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Figure 6: 1H→13C CP-MAS NMR spectra of MSN and MSN-DAMO.
On the top, the assignation to different carbon atoms of DAMO is
shown.
In both cases, δ is minor than 1, showing that the be-
havior is different from a first order kinetic. The k values
varies from 0.021 to 0.51 h−1 for MSN@LEVO and MSN-
DAMO@LEVO, respectively,which couldpoint to strong at-
tractive interactions of the LEVOmolecules with the Si-OH5
groups present in thematrix of pristineMSN, as it has been
demonstrated elsewhere [34].
The effectiveness of the different released LEVO doses
at several times from both MSNs against E. coli and S.
aureus bacterial growth was performed. The counting of10
CFUs after 1, 3 and 24 h showed the efficacy from both ma-
trices against the two tested strains (data not shown).
Figure 7: Cumulative LEVO release profiles from MSN and MSN-
DAMO samples and comparison with Chapman equation.
3.3 Targeting to bacteria wall and biofilm
Regarding targeting to bacteria wall (Figure 8), confocal
images reveal that fluorescentMSN-DAMOare locatednear 15
the E. coli bacteria wall resulting in aggregates of nanopar-
ticles (green dots) on the bacteria’s surface for both tested
concentration. Note than in the case of MSN such green
dots are not observed, probably due to the lack of inter-
action with the bacteria wall and that would be easily re- 20
moved during the washing process.
Concerning targeting to bacterial biofilm, Figure 9 rep-
resents the effect of DAMO functionalization (MSN-DAMO,
green), to E. coli biofilm (blue) investigated by using con-
focal microscopy at different depths. It can be appreci- 25
ated noticeable differences betweenMSN andMSN-DAMO.
Thus, in the case of MSN, the nanoparticles are localized
in the vicinity of the biofilm. However, for MSN-DAMO it
can be observed that the nanoparticles are internalized
within biofilm, demonstrating the capability of this amine- 30
functionalized nanosystem to penetrate the mucopolysac-
charide matrix.
3.4 Nanoantibiotic eflcacy
Once demonstrated the ability of MSN-DAMO nanopar-
ticles to target the bacteria wall and internalize into 35
the biofilm, we measured the effectiveness of the com-
plete nanosystem (MSN-DAMO@LEVO) against a previ-
ously formed S. aureus biofilm. We chose such bacterial
strain since it is the most common responsible of bone in-
fection processes [4]. Figure 10 represents the confocal mi- 40
croscopy study corresponding to the preformed S. aureus
biofilm before and after being treated with MSN@LEVO
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Figure 8: Targeting to E. coli bacteria wall studies by confocal microscopy.
Figure 9: Targeting to E. coli biofilm studies by using confocal microscopy.
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Figure 10: Left: Control biofilm. Right: Biofilm treated with MSN and MSN-DAMO nanosystems.
and MSN-DAMO@LEVO. The results show that the un-
treated biofilm is composed of live bacteria multilayer
(green) with a small amount of dead bacteria (red) coated
by a polysaccharide matrix (blue) with an average thick-
ness of 35 µm. After treatment with MSN@LEVO a remain-5
ing bacteria layer mainly formed by live cells is observed.
Nonetheless, in the case of the full MSN-DAMO@LEVO
nanosystem the complete destruction of biofilm is appreci-
ated, appearing only isolated bacteria, almost negligible.
These results evidence that the incorporation of a target-10
ing agent onto the MSNs platform triggers the complete
biofilm destruction in combination with antibiotics.
4 Conclusions
We have developed a new nanoantibiotic consisting on
mesoporous silica nanoparticles decorated with amine 15
groups on their surface and loaded with levofloxacin into
their mesopores. Amine-functionalization provides this
nanocarrier of a positive charge density that improves the
targeting capability of the nanosystem to bacteria wall
and bacterial biofilm, meanwhile improving the antibi- 20
otic release by achieving faster release kinetics. Microbi-
ological studies against S. aureus biofilms show the com-
plete destruction of biofilm when both elements (antibi-
otic and targeting agents) are synergistically combined in
auniquenanoplatform.Weenvision this nanoantibiotic as 25
a promising alternative to current therapies for the treat-
ment of bone infection.
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